Session Chair Profile
Ph.D., MBA, Senior Vice President, Global Head of R&D, BGI
Dr. Yiwu He is board director of P4 Medicine Institute founded by Dr. Lee Hood in Seattle and chair professor at the University of Science and Technology of China. Before joining BGI, Dr. He was senior program officer and deputy director at the Bill & Melinda Gates Foundation, where he established the foundation’s R&D initiatives in China. His expertise includes precision medicine, biomarkers, sequencing and small molecular drug development in cancer, HIV and other therapeutic areas, as well as vaccine and diagnostic development. He has led numerous medical research partnerships globally and multiple large-scale vaccine development and production programs in China. As director of research technologies at GSK, he led the team that developed platforms for drug development, including protein chip, yeast-2-hybrid, high throughput SNP screening, human disease molecular map and human biomarker library. He also led GSK’s global efforts to use biomarkers to develop drugs and support clinical trials.
Implications of $100 Whole Genome Sequencing
Reductions in cost will move whole genome sequencing (WGS) from mostly research labs to hospitals, becoming a standard diagnostic for all patients. Combined with other healthcare advancements, WGS will benefit patients with more precise diagnosis and better treatments. Additionally, WGS will be more closely integrated with drug development.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: We explore the healthcare impact of a $100 genome. Whole Genome Sequencing at consumer pricing will give healthcare providers a wealth of information on genetic links, risk factors of diseases, drug targets and drug reactions. The availability of precision medicine will benefit patients and society while lowering cost.